Mereo BioPharma Group plc
Index- P/E- EPS (ttm)-3.33 Insider Own- Shs Outstand124.99M Perf Week-10.35%
Market Cap88.35M Forward P/E- EPS next Y- Insider Trans- Shs Float124.99M Perf Month-21.99%
Income- PEG- EPS next Q- Inst Own58.19% Short Float / Ratio3.06% / 4.44 Perf Quarter26.66%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Interest3.83M Perf Half Y-19.67%
Book/sh-0.22 P/B- EPS next Y- ROA- Target Price4.25 Perf Year-32.03%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.30 - 1.85 Perf YTD-5.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.79% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low134.85% ATR0.09
Employees49 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)36.03 Volatility9.28% 10.85%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.04 Prev Close0.71
ShortableYes LT Debt/Eq- EarningsMar 28 AMC Payout0.00% Avg Volume862.40K Price0.71
Recom1.50 SMA20-13.85% SMA50-22.55% SMA200-29.37% Volume898,778 Change-0.52%
Aug-12-22Initiated Cantor Fitzgerald Overweight $4
May-05-21Initiated BTIG Research Buy $10
Apr-05-21Initiated Needham Buy $10
Mar-28-23 04:30PM
Mar-21-23 06:30AM
Feb-08-23 07:00AM
Jan-10-23 05:35AM
Nov-15-22 09:35AM
07:00AM Loading…
Nov-08-22 07:00AM
Nov-02-22 04:01PM
Oct-28-22 07:00AM
Oct-24-22 04:30PM
Oct-21-22 07:00AM
Oct-18-22 11:58AM
Oct-17-22 07:00AM
Oct-03-22 05:00PM
09:21AM Loading…
Sep-28-22 09:21AM
Sep-26-22 07:00AM
Sep-14-22 09:00AM
Sep-12-22 08:00AM
Sep-09-22 08:22PM
Aug-31-22 07:00AM
Aug-22-22 04:00AM
Jul-05-22 04:01PM
Jun-21-22 08:30AM
Jun-20-22 10:36AM
Jun-17-22 05:30PM
Jun-02-22 08:00AM
05:05PM Loading…
May-26-22 05:05PM
May-17-22 08:00AM
May-09-22 07:45AM
May-06-22 05:12PM
Apr-22-22 09:35AM
Apr-06-22 08:00AM
Mar-31-22 04:01PM
Mar-03-22 08:30AM
Mar-01-22 08:00AM
Feb-10-22 08:00AM
Jan-12-22 01:59PM
Dec-29-21 01:19AM
Dec-22-21 07:00AM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-13-21 07:00AM
Dec-10-21 09:38PM
Nov-30-21 07:00AM
Nov-09-21 08:00AM
Nov-04-21 09:00AM
Oct-31-21 10:30AM
Oct-26-21 10:26AM
Oct-13-21 08:00AM
Oct-01-21 04:31PM
Sep-20-21 08:00AM
Sep-09-21 08:00AM
Aug-02-21 08:00AM
Jul-19-21 07:04PM
Jun-02-21 09:45AM
May-27-21 08:00AM
May-04-21 08:00AM
Apr-30-21 08:00AM
Apr-08-21 08:30AM
Mar-31-21 05:02PM
Feb-25-21 11:33AM
Feb-18-21 07:00AM
Feb-12-21 12:41PM
Feb-10-21 07:00AM
Feb-09-21 04:03PM
Dec-21-20 10:26AM
Dec-18-20 11:15AM
Dec-17-20 04:05PM
Dec-15-20 01:00PM
Dec-07-20 10:59PM
Nov-23-20 07:05AM
Nov-16-20 07:00AM
Nov-10-20 07:23AM
Oct-20-20 07:00AM
Oct-19-20 07:00AM
Sep-29-20 07:00AM
Sep-24-20 07:00AM
Sep-16-20 08:00AM
Sep-04-20 05:08AM
Aug-25-20 07:00AM
Aug-17-20 03:30PM
Jun-30-20 07:00AM
Jun-16-20 07:00AM
Jun-04-20 07:00AM
Mar-27-20 08:00AM
Feb-28-20 07:00AM
Feb-19-20 07:21AM
Feb-12-20 08:00AM
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.